Ad hoc announcement pursuant to Art. 53 LR Basel, October 29, 2024 – Novartis announced today that Scemblix® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
Press Release: Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - Newscast
Wed, 12 Mar 2025 13:00:00 GMT Winters did not stand for re-electionShareholders approved all other proposals by the Board of Directors, including the reduction of share capital, the 2024 report on Novartis announced today it ...
Mon, 09 Dec 2024 11:33:00 GMT Fabhalta obtained FDA approval in December 2023 for the treatment ... NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST ...
Tue, 29 Oct 2024 17:01:00 GMT Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential. First-in-class STAMP ...
Fri, 31 May 2024 07:30:00 GMT Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.
